Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert A. Lewis, A.A. Roger Thompson, Catherine G. Billings, Athanasios Charalampopoulos, Charlie A. Elliot, Neil Hamilton, Catherine Hill, Judith Hurdman, Smitha Rajaram, Ian Sabroe, Andy J. Swift, David G. Kiely, Robin Condliffe. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020

Member's Comments

No comment yet.

Related content which might interest you: The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Histopathology of idiopathic pulmonary arterial hypertension in patients with low or normal diffusion capacity Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses Source: Eur Respir J 2013; 42: 1575-1585 Year: 2013 ‘Idiopathic‘ pulmonary arterial hypertension with preserved lung function but co-existing parenchymal abnormalities: Response to treatment and survival Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Severe pulmonary hypertension in lung disease: phenotypes and response to treatment Source: Eur Respir J 2015; 46: 1378-1389 Year: 2015 Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Determination of pulmonary hypertension degree in patients with interstitial lung diseases Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (1) 1701214; 10.1183/13993003.01214-2017 Year: 2018 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia Source: Eur Respir J, 52 (1) 1800545; 10.1183/13993003.00545-2018 Year: 2018 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Diaphragm dysfunction in combination with lung function decline is associated with higher mortality in idiopathic pulmonary fibrosis patients Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018